Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a diabetes drug protect the heart after a massive attack?

NCT ID NCT06174753

Disease control Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether dapagliflozin, a diabetes drug, can limit heart muscle damage in people having a major heart attack (STEMI). Participants receive either the drug or a placebo for 7 days, and heart damage is measured with an MRI. The goal is to see if this drug can improve recovery and reduce future heart problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dapagliflozin (a diabetes drug that may protect the heart)
What this could lead to
If it works, this could show that dapagliflozin reduces heart muscle damage after a heart attack, potentially improving recovery and lowering future heart risks.
What could go wrong
This is a relatively small phase 3 trial (256 people) focused on a specific type of heart attack. The drug may not reduce damage as hoped, and side effects like dehydration or infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 256 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients referred for PPCI meeting the following criteria are eligible for the study: * Ischemic chest discomfort of ≥30 minutes duration, and * Onset of chest pain ≤12 hours prior to entry into the study, and * One of the following High-Risk criteria on a standard 12 lead ECG: a. Anterior STEMI with ST-segment elevation ≥2mm (0.2 mV) in each of at least 2 contiguous precordial leads (V1-V6) b. Extensive non-anterior STEMI defined as ST-segment elevation of \>1mm in two or more contiguous non-anterior leads accompanied by i. 8 or more leads with \> 1 mm ST elevation or depression, or both; OR ii. Sum of ST- segment elevation \>20mm Exclusion Criteria: * Age \< 18 years * Any contraindication to undergo CMR imaging * Killip 4 (Cardiogenic shock on presentation) * Therapy with SGLT2i within last 8 weeks * Type 1 diabetes mellitus * Pregnancy * Nursing mother * Unwilling to use appropriate forms of contraception, as applicable * Chronic symptomatic HF with prior hospitalization for HF within the last year * hospitalization * Known history of prior MI * Any non-CV condition with a life expectancy of less than one year * Previous randomization in the present study * Participation in a study with another investigational device or drug \< four weeks * Inability to provide informed consent * Confirmed ketoacidosis at time of admission * Known severe hepatic impairment (Cirrhosis) * Severe renal impairment (eGFR \< 30 mL/min1.73m2 (based on prior or baseline blood work) * Known severe valvular heart disease * Need for CABG within 90 days based on the results of the initial coronary angiogram * False positive STEMI (based on the results of the coronary angiogram)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myocardial infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction ST elevation myocardial infarction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Ottawa Heart Institute

    RECRUITING

    Ottawa, Ontario, K1Y 4W7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.